News

September 14, 2017September 14, 2017

Rocapuldencel-T Improves Survival in Renal Cell Carcinoma Patients, Phase 3 Trial Suggests

News

Adding Rocapuldencel-T (AGS-003) to standard-of-care treatment may lengthen the survival of patients with newly diagnosed metastatic renal cell carcinoma, according to data presented at the European Society for Medical Oncology (ESMO) ... Read more

September 14, 2017

Immuno-oncology Becoming Established as Fifth Pillar of Cancer Therapy, Analysts Say

News

The analytics firm Global Data argues that immuno-oncology appears set to become a fifth pillar among the mainstay of cancer treatments made up of surgery, radiotherapy, chemotherapy, and other ... Read more

September 13, 2017

Experts Discuss Role of Cancer Immunotherapy at Bristol-Myers Presentation, Panel Discussion

News

In just three years, Bristol-Myers Squibb (BMS) received more than 10 approvals for Opdivo (nivolumab), authored 12 publications in the New England Journal of Medicine, and was granted seven Breakthrough Therapy designations by ... Read more

September 13, 2017September 13, 2017

Opdivo and Yervoy Combo Boosts Mesothelioma Survival, Phase 2 Clinical Trial Shows

News

More than half of the mesothelioma patients who received a combination of Bristol-Myers Squibb‘s checkpoint blockers Opdivo (nivolumab) and Yervoy (ipilimumab) lived a year or more after treatment, according to ... Read more

September 12, 2017September 12, 2017

Ionis’ Antisense Therapy Shows Promising Results when Combined with Imfinzi in Head and Neck Cancers

News

Ionis Pharmaceuticals’ IONIS-STAT3-2.5 (AZD9150) showed promising results when given in combination with AstraZeneca’s Imfinzi (durvalumab) to patients with refractory and metastatic head and neck cancer in a small clinical trial. ... Read more

September 12, 2017September 12, 2017

Keytruda Continues to Show Promise in Advanced Stomach Cancer Patients, Updated KEYNOTE-059 Data Show

News

Keytruda (pembrolizumab) is safe and has shown promising anti-tumor activity in patients with advanced gastric or gastroesophageal junction (GEJ) cancer, according to data presented at the European Society for Medical Oncology ... Read more

September 11, 2017September 11, 2017

Opdivo Improves Long-Term Survival in Advanced Lung Cancer, Data Show

News

Opdivo (nivolumab) outperformed the cancer drug Taxotere (docetaxel) in clinical trials of advanced and earlier treated lung cancer, with survival rates about double those seen with the older treatment ... Read more

September 11, 2017

Imugene Begins Phase 1b/2 Clinical Trial of HER-Vaxx Vaccine for Stomach Cancer

News

The first patient has been dosed in a Phase 1b/2 trial evaluating Imugene’s stomach cancer vaccine HER-Vaxx. Researchers are still recruiting participants. They hope to enroll 18 patients at eight ... Read more

September 8, 2017September 8, 2017

Opdivo, Yervoy Combo Lengthens Survival Time in Renal Cell Carcinoma Patients, Supporting Early Trial End

News

The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) was more effective in prolonging the lives of newly diagnosed metastatic renal cell carcinoma patients than the current standard of care, Sutent (sunitinib), new data ... Read more

September 7, 2017September 7, 2017

FDA Suspends UCART123 Trials After Patient Death

News

The U.S. Food and Drug Administration (FDA) has suspended two Phase 1 trials assessing Cellectis’ CAR T-cell therapy UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) after the ... Read more